Quantcast

Announcing the Lumixyl(TM) Brightening System, a New Physician-Grade System Designed to Safely Address the Signs of Hyperpigmentation

March 9, 2010

NEW YORK, March 9 /PRNewswire/ — Envy Medical, Inc., introduces the new Lumixyl(TM) Brightening System, a revolutionary multi-faceted approach to effectively treat hyperpigmentation without irritation or other side effects associated with prescription Hydroquinone or retinoids. This professional skincare system introduction builds on the success of the Lumixyl Topical Brightening Creme introduced in 2009.

“The Lumixyl Topical Brightening System is an entirely new approach to naturally brighter, more vibrant skin, representing a new physician-grade standard in skincare,” explains Dr. Basil Hantash, MD, PhD, a board certified Stanford-trained dermatologist and vice-chairman of the board at Envy Medical, who also helped develop the Lumixyl peptide technology.

An innovation in skin brightening technology, the four products in the Lumixyl Brightening System work synergistically to target existing hyperpigmentation and to prevent its recurrence. For most patients these formulations can eliminate the need to use hydroquinone or its bi-products, which are controversial due to their potential side effects. Lumixyl products are proven to be powerful but gentle on skin.

“Physicians and the public at large have been calling for a viable alternative to prescription hydroquinone therapies,” commented Envy Medical CEO, Curtis A. Cluff. “We are very pleased to be able to answer that call with a system that provides visible brightening with a safe and non-irritating formula.”

The Lumixyl Topical Brightening System builds on the four products including Active-Prep Cleanser, the Topical Brightening Creme, GlycoPeel 20 Rapid Exfoliating Lotion, and Moisture-Lock Sunscreen SPF 30. The products are ideal for all skin types. Lumixyl Brightening System retails for $270 for four full size products.

Developed by Envy Medical, Inc. and dermatological researchers at Stanford University, Lumixyl products are made exclusively for dermatologists, plastic surgeons and skin oriented aesthetic physicians. The products are manufactured and sold by Envy Medical in the United States and distributed internationally by Toronto Canada-based BASIS Medical Technologies.

ABOUT BASIS — BASIS Medical Technologies specializes in the development and distribution of groundbreaking technologies in medicine and medical aesthetics. Headquartered in Toronto, Canada, BASIS is an innovative technology platform with sales, marketing and training capabilities around the world. With an experienced management team and medical advisory panel, BASIS is committed to delivering and developing cutting-edge medical products internationally. BASIS is an exclusive market representative for Lumixyl in markets throughout the world, a product licensed by Envy Medical Inc.

ABOUT ENVY MEDICAL — Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com.

For more information on Lumixyl or to locate a dispensing physician near you, please contact: info@envymedical.com (within the US) or info@basismedtech.com (international).

SOURCE Envy Medical, Inc.


Source: newswire



comments powered by Disqus